High-Drug-Load Oral Tablets With Dry Granulation Manufacturability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing solid dosage forms of the compound of Formula I have low drug loading, which affects their size, swallowability, and patient compliance, and high drug loading poses challenges due to the dominance of excipient properties over the API's physical properties, making manufacturability difficult.
Innovation Solution
Formulations comprising 40-70 wt% of Formula I, 20-60 wt% filler, 1-10 wt% disintegrating agent, and 0.5-5 wt% lubricant, particularly using microcrystalline cellulose, crospovidone, and magnesium stearate, enable high drug loading through a dry granulation process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If low drug loading formulations are used, then manufacturability is improved through excipient dominance, but drug loading is low affecting tablet size and patient compliance
Solution Approach 1:
The patent changes the drug loading parameter from conventional low levels (typically <25%) to high levels (40-70%), fundamentally altering the formulation composition. This parameter change requires selecting excipients and processing conditions specifically optimized for high drug loading, such as using microcrystalline cellulose as filler and adjusting granulation parameters to maintain manufacturability despite the shift in composition balance.
Solution Approach 2:
The patent creates a composite formulation system where the API dominates the physical properties (40-70% content) rather than being a minor component. This composite approach requires careful selection of compatible excipients (fillers, binders, lubricants) that can work effectively with high API content, transforming the formulation from excipient-dominated to API-dominated composite material system.
2Volume of moving object
If high drug loading formulations are used, then tablet size is reduced improving swallowability, but manufacturability becomes difficult due to API physical property dominance
Solution Approach 1:
The patent optimizes granulation parameters specifically for high drug loading conditions, adjusting variables such as granulation speed, moisture content, and processing time to achieve adequate granule formation when API content is 40-70%. This parameter optimization compensates for the loss of excipient-dominated flow and compression characteristics.
Solution Approach 2:
The patent uses specific excipients as intermediaries to facilitate manufacturability in high drug loading formulations. For example, microcrystalline cellulose acts as a mediator providing necessary flow and compression properties, while binders serve as intermediaries to achieve adequate granule formation and tablet binding when the API dominates the formulation composition.
3Ease of operation
If drug loading exceeds 40%, then patient compliance is improved through reduced tablet count, but formulation stability and manufacturability become challenging
Solution Approach 1:
The patent develops a stable composite material system where API (40-70%) is combined with carefully selected excipients in specific ratios. This composite formulation ensures physical and chemical stability through compatible material selection, preventing issues such as caking, segregation, or degradation that typically arise when API content exceeds conventional levels.
Solution Approach 2:
The patent optimizes the local composition and properties of different formulation components to ensure stability. This includes selecting excipients with specific characteristics (particle size, surface area, hygroscopicity) that complement the high API content, creating localized compatibility within the formulation system to maintain overall stability and manufacturability.
Data Source
AI summary
Pharmaceutical formulations, particularly solid oral dosage forms (e.g., tablets) comprising (i) the compound of Formula I in an amount of about 40 wt % to about 70 wt %, (ii) a filler, (iii) a disintegrating agent, (iv) and a lubricant are disclosed, as are uses thereof.